{
    "nctId": "NCT00720031",
    "title": "Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "HLA-A2 melanoma patients"
                    },
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "loco-regional or lymph node metastasis"
                            },
                            {
                                "type": "variable",
                                "value": "transit nodules not surgically resectable"
                            },
                            {
                                "type": "variable",
                                "value": "measurable cutaneous or visceral metastasis"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Patients' tumor express Melan-A/MART-1 antigen"
                    },
                    {
                        "type": "variable",
                        "value": "No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion"
                    },
                    {
                        "type": "variable",
                        "value": "No other melanoma treatment during the protocol"
                    },
                    {
                        "type": "variable",
                        "value": "Life expectancy should be greater than 6 months"
                    },
                    {
                        "type": "variable",
                        "value": "General state with Karnowsky greater than 80, ECOG = 0, 1 or 2"
                    },
                    {
                        "type": "variable",
                        "value": "Patient should be negative for HIV and B and C hepatitis"
                    },
                    {
                        "type": "variable",
                        "value": "Biological parameters at the beginning of the study: leucocytes \u2265 2000 elements per mm3, hemoglobin \u2265 10.5g/dl, platelets \u2265 100 000 per mm3, phosphatases alcalines transaminases \u2264 1 time 1/2 compared to the normal"
                    },
                    {
                        "type": "variable",
                        "value": "Signed informed consent"
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 18 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Cardio-vascular pathologies, evoluting and uncontrolled, (severe HTA), cardiac deficiency, severe angor, severe arrhythmia"
                            },
                            {
                                "type": "variable",
                                "value": "Infectious pathologies evoluting and requiring antibiotherapy"
                            },
                            {
                                "type": "variable",
                                "value": "Patients HIV+"
                            },
                            {
                                "type": "variable",
                                "value": "Transplanted patients or patients suffering from severe auto-immune disease"
                            },
                            {
                                "type": "variable",
                                "value": "Psychiatric troubles that do not allow the protocol follow-up"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or breast-feeding women"
                            },
                            {
                                "type": "variable",
                                "value": "No contraception"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Biological parameters at the beginning of the study: leucocytes \u2265 2000 elements per mm3, hemoglobin \u2265 10.5g/dl, platelets \u2265 100 000 per mm3, phosphatases alcalines transaminases \u2264 1 time 1/2 compared to the normal'), Symbol('General state with Karnowsky greater than 80, ECOG = 0, 1 or 2'), Symbol('HLA-A2 melanoma patients'), Symbol('Life expectancy should be greater than 6 months'), Symbol('Must have minimum age of 18 Years'), Symbol('No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion'), Symbol('No other melanoma treatment during the protocol'), Symbol('Patient should be negative for HIV and B and C hepatitis'), Symbol(\"Patients' tumor express Melan-A/MART-1 antigen\"), Symbol('Signed informed consent'), Or(Symbol('loco-regional or lymph node metastasis'), Symbol('measurable cutaneous or visceral metastasis'), Symbol('transit nodules not surgically resectable')), Not(Or(Symbol('Cardio-vascular pathologies, evoluting and uncontrolled, (severe HTA), cardiac deficiency, severe angor, severe arrhythmia'), Symbol('Infectious pathologies evoluting and requiring antibiotherapy'), Symbol('No contraception'), Symbol('Patients HIV+'), Symbol('Pregnant or breast-feeding women'), Symbol('Psychiatric troubles that do not allow the protocol follow-up'), Symbol('Transplanted patients or patients suffering from severe auto-immune disease'))))"
}